A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
BeOne Medicines
Novartis
AstraZeneca
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Kivu Bioscience Inc.
AstraZeneca
BeOne Medicines
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
Pfizer
Ohio State University Comprehensive Cancer Center
Iambic Therapeutics, Inc
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jazz Pharmaceuticals
Fred Hutchinson Cancer Center
Novartis
Memorial Sloan Kettering Cancer Center
Amgen
Genmab
Fate Therapeutics
Conjupro Biotherapeutics, Inc.
Wake Forest University Health Sciences
DualityBio Inc.
National Institutes of Health Clinical Center (CC)
Actuate Therapeutics Inc.
Conjupro Biotherapeutics, Inc.
NRG Oncology
NRG Oncology
Mayo Clinic
Astellas Pharma Inc
Institut Cancerologie de l'Ouest
University of Vic - Central University of Catalonia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
City of Hope Medical Center
GlaxoSmithKline
SystImmune Inc.
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Orano Med LLC
Brigham and Women's Hospital
Dragonfly Therapeutics
Stanford University
Bristol-Myers Squibb
Filamon LTD
PMV Pharmaceuticals, Inc